Understanding how RBM10 loss affects immune escape in KRAS-mutant lung cancer
Official title: Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11321289 · Data updated 2026-11-12
This research aims to understand why some KRAS-mutant lung cancers resist immune therapy and how RBM10 loss changes tumor immunity, with the goal of finding new ways to help patients respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | May 2, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $370,575 |
| NIH project number | 5R01CA272570-04 |
| Project ID | NIH-11321289 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include patients with KRAS-mutant non-small cell lung cancer, particularly those whose tumors show RBM10 alterations or related splicing abnormalities.
✕Less likely to help
Patients without KRAS-mutant NSCLC or RBM10 alterations may not benefit from the specific mechanisms studied here.
What this research studies
In KRAS-mutant non-small cell lung cancer, immune checkpoint inhibitors work for some patients but many do not benefit long-term. The study investigates how losing RBM10, a gene that controls alternative splicing, drives DNA damage and immune signaling that can create a tumor-friendly environment. It will use cell lines and animal models to explore the pathways linking RBM10 loss to STING/NF-κB signaling and to identify potential targets like CSF1R to improve therapy. The work could point to new combination strategies to enhance responses to immunotherapy in patients with this cancer subtype.
Why it matters
Potential benefit: If successful, the findings could lead to new treatment approaches that make immune therapies work better for KRAS-mutant LUAD patients.
How similar studies have gone: Preliminary data suggest RBM10 and splicing alterations influence tumor immunity, supporting exploration of this approach, though translation to patients is ongoing.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Skoulidis, Ferdinandos — University of Tx Md Anderson Can Ctr
- Study coordinator: Skoulidis, Ferdinandos
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.